Biosimilars
TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.56, ss.75-76, 2022 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 56
- Basım Tarihi: 2022
- Doi Numarası: 10.4274/turkderm.galenos.2022.06978
- Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.75-76
- Anahtar Kelimeler: Psoriasis, biosimilars, biologics
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Bursa Uludağ Üniversitesi Adresli: Evet
Özet
For a drug to be defined as a biosimilar, it should be fairly similar to the previously approved original or reference product. The minor variances in its inactive ingredients should not pose clinically significant differences from the reference product in terms of safety and efficacy potency. Biosimilars of infliximab and adalimumab have received reimbursements in our country. By lowering treatment costs, biosimilars may provide considerable economies for health systems that reimburse healthcare expenditures.